SuperworthAkebia Therapeutics shares outstanding AKBA
Diluted shares outstanding, averaged over each quarter, from 2013.
- Latest quarter, to Jun 30, 2026
- 269.6M
- On a year earlier
- −0.6%
- fewer shares
Akebia Therapeutics had 269.6M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 0.6% fewer than a year earlier, so each share owns a little more of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 265.4M | +21% |
| FY2024 | 218.7M | +15% |
| FY2023 | 189.9M | +3% |
| FY2022 | 184M | +5% |
| FY2021 | 174.6M | +20% |
| FY2020 | 145.1M | +22% |
| FY2019 | 119.4M | +72% |
| FY2018 | 69.4M | +47% |
| FY2017 | 47.4M | +24% |
| FY2016 | 38.3M | +26% |
| FY2015 | 30.3M | +53% |
| FY2014 | 19.8M | +2964% |
| FY2013 | 646.6K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 269.6M | −1% | |
| Q1 FY26 | 267M | +11% | |
| Q4 FY25 | 265.4M | +21% | |
| Q3 FY25 | 274.4M | +30% | |
| Q2 FY25 | 271.1M | +29% | |
| Q1 FY25 | 241.6M | +18% | |
| Q4 FY24 | 218.7M | +15% | |
| Q3 FY24 | 210.3M | +12% | |
| Q2 FY24 | 209.7M | +12% | |
| Q1 FY24 | 205M | +11% | |
| Q4 FY23 | 189.9M | +3% | |
| Q3 FY23 | 188.3M | +2% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Akebia Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.